Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma

Neeraj K. Saxena, Ping P. Fu, Arumugam Nagalingam, Jason Wang, Jeffrey Handy, Cynthia Cohen, Mourad Tighiouart, Dipali Sharma, Frank A. Anania

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background & Aims: Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma (HCC). Lower adiponectin levels are associated with poor prognosis in obese HCC patients, hence it is plausible that adiponectin acts as a negative regulator of HCC. We investigated the effects of adiponectin on HCC development and its molecular mechanisms. Methods: Assays with Huh7 and HepG2 HCC cells were used to examine the signal transduction pathways involved in the protective functions of adiponectin in HCC. These studies were followed by in vivo approaches using HCC xenografts and tumor analysis. Results: from in vitro and in vivo findings were corroborated using human HCC tissue microarray and analysis of clinicopathological characteristics. Results Adiponectin increased apoptosis of HCC cells through activation of caspase-3. Adiponectin increased phosphorylation of c-Jun-N-terminal kinase (JNK) and inhibition of c-Jun-N-terminal kinase-phosphorylation inhibited adiponectin-induced apoptosis and caspase-3 activation. Adiponectin increased phosphorylation of 5′-adenosine monophosphate-activated protein kinase and tumor suppressor tuberous sclerosis complex 2 and inhibited mammalian target of rapamycin phosphorylation. Inhibition of 5′-adenosine monophosphate-activated protein kinase phosphorylation not only inhibited adiponectin-induced c-Jun-N-terminal kinase phosphorylation, but also blocked biological effects of adiponectin. Adiponectin substantially reduced liver tumorigenesis in nude mice. Importantly, analysis of adiponectin expression levels in tissue microarray of human HCC patients revealed an inverse correlation of adiponectin expression with tumor size. Conclusions: Adiponectin protects against liver tumorigenesis; its reduced expression is associated with poor prognosis in obese patients with HCC.

Original languageEnglish (US)
JournalGastroenterology
Volume139
Issue number5
DOIs
StatePublished - Nov 2010

Fingerprint

Adiponectin
Sirolimus
Hepatocellular Carcinoma
Phosphotransferases
Phosphorylation
JNK Mitogen-Activated Protein Kinases
Adenosine Monophosphate
Caspase 3
Protein Kinases
Carcinogenesis
Tissue Array Analysis
Apoptosis
Neoplasms
Tuberous Sclerosis
Liver
Heterografts
Nude Mice
Epidemiologic Studies
Signal Transduction

Keywords

  • Adiponectin
  • Hepatocellular Carcinoma
  • mTOR
  • TSC2

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. / Saxena, Neeraj K.; Fu, Ping P.; Nagalingam, Arumugam; Wang, Jason; Handy, Jeffrey; Cohen, Cynthia; Tighiouart, Mourad; Sharma, Dipali; Anania, Frank A.

In: Gastroenterology, Vol. 139, No. 5, 11.2010.

Research output: Contribution to journalArticle

Saxena, NK, Fu, PP, Nagalingam, A, Wang, J, Handy, J, Cohen, C, Tighiouart, M, Sharma, D & Anania, FA 2010, 'Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma', Gastroenterology, vol. 139, no. 5. https://doi.org/10.1053/j.gastro.2010.07.001
Saxena, Neeraj K. ; Fu, Ping P. ; Nagalingam, Arumugam ; Wang, Jason ; Handy, Jeffrey ; Cohen, Cynthia ; Tighiouart, Mourad ; Sharma, Dipali ; Anania, Frank A. / Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. In: Gastroenterology. 2010 ; Vol. 139, No. 5.
@article{c41eb629f53a48a2a09d74c656e87e3b,
title = "Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma",
abstract = "Background & Aims: Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma (HCC). Lower adiponectin levels are associated with poor prognosis in obese HCC patients, hence it is plausible that adiponectin acts as a negative regulator of HCC. We investigated the effects of adiponectin on HCC development and its molecular mechanisms. Methods: Assays with Huh7 and HepG2 HCC cells were used to examine the signal transduction pathways involved in the protective functions of adiponectin in HCC. These studies were followed by in vivo approaches using HCC xenografts and tumor analysis. Results: from in vitro and in vivo findings were corroborated using human HCC tissue microarray and analysis of clinicopathological characteristics. Results Adiponectin increased apoptosis of HCC cells through activation of caspase-3. Adiponectin increased phosphorylation of c-Jun-N-terminal kinase (JNK) and inhibition of c-Jun-N-terminal kinase-phosphorylation inhibited adiponectin-induced apoptosis and caspase-3 activation. Adiponectin increased phosphorylation of 5′-adenosine monophosphate-activated protein kinase and tumor suppressor tuberous sclerosis complex 2 and inhibited mammalian target of rapamycin phosphorylation. Inhibition of 5′-adenosine monophosphate-activated protein kinase phosphorylation not only inhibited adiponectin-induced c-Jun-N-terminal kinase phosphorylation, but also blocked biological effects of adiponectin. Adiponectin substantially reduced liver tumorigenesis in nude mice. Importantly, analysis of adiponectin expression levels in tissue microarray of human HCC patients revealed an inverse correlation of adiponectin expression with tumor size. Conclusions: Adiponectin protects against liver tumorigenesis; its reduced expression is associated with poor prognosis in obese patients with HCC.",
keywords = "Adiponectin, Hepatocellular Carcinoma, mTOR, TSC2",
author = "Saxena, {Neeraj K.} and Fu, {Ping P.} and Arumugam Nagalingam and Jason Wang and Jeffrey Handy and Cynthia Cohen and Mourad Tighiouart and Dipali Sharma and Anania, {Frank A.}",
year = "2010",
month = "11",
doi = "10.1053/j.gastro.2010.07.001",
language = "English (US)",
volume = "139",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma

AU - Saxena, Neeraj K.

AU - Fu, Ping P.

AU - Nagalingam, Arumugam

AU - Wang, Jason

AU - Handy, Jeffrey

AU - Cohen, Cynthia

AU - Tighiouart, Mourad

AU - Sharma, Dipali

AU - Anania, Frank A.

PY - 2010/11

Y1 - 2010/11

N2 - Background & Aims: Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma (HCC). Lower adiponectin levels are associated with poor prognosis in obese HCC patients, hence it is plausible that adiponectin acts as a negative regulator of HCC. We investigated the effects of adiponectin on HCC development and its molecular mechanisms. Methods: Assays with Huh7 and HepG2 HCC cells were used to examine the signal transduction pathways involved in the protective functions of adiponectin in HCC. These studies were followed by in vivo approaches using HCC xenografts and tumor analysis. Results: from in vitro and in vivo findings were corroborated using human HCC tissue microarray and analysis of clinicopathological characteristics. Results Adiponectin increased apoptosis of HCC cells through activation of caspase-3. Adiponectin increased phosphorylation of c-Jun-N-terminal kinase (JNK) and inhibition of c-Jun-N-terminal kinase-phosphorylation inhibited adiponectin-induced apoptosis and caspase-3 activation. Adiponectin increased phosphorylation of 5′-adenosine monophosphate-activated protein kinase and tumor suppressor tuberous sclerosis complex 2 and inhibited mammalian target of rapamycin phosphorylation. Inhibition of 5′-adenosine monophosphate-activated protein kinase phosphorylation not only inhibited adiponectin-induced c-Jun-N-terminal kinase phosphorylation, but also blocked biological effects of adiponectin. Adiponectin substantially reduced liver tumorigenesis in nude mice. Importantly, analysis of adiponectin expression levels in tissue microarray of human HCC patients revealed an inverse correlation of adiponectin expression with tumor size. Conclusions: Adiponectin protects against liver tumorigenesis; its reduced expression is associated with poor prognosis in obese patients with HCC.

AB - Background & Aims: Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma (HCC). Lower adiponectin levels are associated with poor prognosis in obese HCC patients, hence it is plausible that adiponectin acts as a negative regulator of HCC. We investigated the effects of adiponectin on HCC development and its molecular mechanisms. Methods: Assays with Huh7 and HepG2 HCC cells were used to examine the signal transduction pathways involved in the protective functions of adiponectin in HCC. These studies were followed by in vivo approaches using HCC xenografts and tumor analysis. Results: from in vitro and in vivo findings were corroborated using human HCC tissue microarray and analysis of clinicopathological characteristics. Results Adiponectin increased apoptosis of HCC cells through activation of caspase-3. Adiponectin increased phosphorylation of c-Jun-N-terminal kinase (JNK) and inhibition of c-Jun-N-terminal kinase-phosphorylation inhibited adiponectin-induced apoptosis and caspase-3 activation. Adiponectin increased phosphorylation of 5′-adenosine monophosphate-activated protein kinase and tumor suppressor tuberous sclerosis complex 2 and inhibited mammalian target of rapamycin phosphorylation. Inhibition of 5′-adenosine monophosphate-activated protein kinase phosphorylation not only inhibited adiponectin-induced c-Jun-N-terminal kinase phosphorylation, but also blocked biological effects of adiponectin. Adiponectin substantially reduced liver tumorigenesis in nude mice. Importantly, analysis of adiponectin expression levels in tissue microarray of human HCC patients revealed an inverse correlation of adiponectin expression with tumor size. Conclusions: Adiponectin protects against liver tumorigenesis; its reduced expression is associated with poor prognosis in obese patients with HCC.

KW - Adiponectin

KW - Hepatocellular Carcinoma

KW - mTOR

KW - TSC2

UR - http://www.scopus.com/inward/record.url?scp=78049478003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049478003&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2010.07.001

DO - 10.1053/j.gastro.2010.07.001

M3 - Article

C2 - 20637208

AN - SCOPUS:78049478003

VL - 139

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -